Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T19:41:18.868Z.
Calculation as of: 2026-10-06T19:41:18.868Z.
Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0cade57d6bc8828dc71ac364ddc44a4328d7c948fb2699a56d4eea8e3f6e5b7
EARNINGS YIELD
N/A
Market Cap
$1.33B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.34B
Earnings Yield
9.29%
TTM Avg
10.12%
3Y Avg
14.35%
5Y Avg
46.70%
Market Cap
$1.37B
Earnings Yield
N/A
TTM Avg
818.17%
3Y Avg
818.17%
5Y Avg
818.17%
Market Cap
$1.39B
Earnings Yield
2.25%
TTM Avg
2.55%
3Y Avg
2.59%
5Y Avg
2.14%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.31B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | 9.29% | 10.12% | 14.35% | 46.70% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | 818.17% | 818.17% | 818.17% |
| Omada Health (OMDA)vs › | $1.23B | 0.30% | 0.29% | 0.29% | 0.29% |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 2.25% | 2.55% | 2.59% | 2.14% |
| Kardigan, Inc. (KARD)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.22B | 5.54% | 3.84% | 4.37% | 4.37% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.22B | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
